The Zuellig Group sells minority interest in Invida

The Zuellig Group announce it has sold its minority interest in Invida, a drug commercial solutions joint venture, to the Italy-based Menarini Group, which is acquiring Invida in its entirety.  Invida was formed in 2005 by The Zuellig Group, Quintiles and Asia investment company Temasek Holdings (Private) Limited.

Invida currently provides biopharmaceutical product sales support in 13 markets in the Asia Pacific region.

Active in the region since 1912, The Zuellig Group remains committed to Asia Pacific.  Zuellig Pharma, a key member of The Zuellig Group’s portfolio of companies and a leading Asia Pacific healthcare supply chain services provider, currently operates in fourteen Asian countries representing over 125 multinational pharmaceuticals manufacturers.  “Commercialization services in areas where we operate are a key part of Zuellig Pharma’s long term strategic roadmap,” said Roland Bruhin, CEO of Healthcare Distribution and Commercialization at Zuellig Pharma.  “Continual investment in this area enables Zuellig Pharma to further enhance our strategic relevance within the healthcare value chain, and our position as a key market partner the manufacturers can depend upon.”

About Zuellig Pharma

Established in 1939, Zuellig Pharma is Asia Pacific's leading healthcare supply chain services provider, covering: inventory management; warehousing; distribution; customer order management; clinical trial logistics; patient-based solutions; provision of sales and marketing solutions; and retail management assistance.

Representing more than 125 multinational pharmaceuticals manufacturers in 14 countries and regions, the company’s 9,000 employees serve more than 250,000 customers including doctors, hospitals, pharmacies and clinics and has emerged as the region’s leading healthcare distribution solution specialist.